Partnerships

We are committed to working with partners to deliver innovative new medicines, vaccines and consumer healthcare products. We know that great ideas come from outside our company as well as inside it. That's why collaborating with others is a fundamental part of our business strategy.

In Singapore we have a wide range of partnerships with government, academia and other businesses to drive innovation.

GSK-EDB Scholarship Trust

In 1990, a S$50 million scholarship trust, jointly funded by GSK and Singapore's EDB (Economic Development Board) was established.

Focused on technical and scientific programmes, the trust funds 30 of Singapore brightest young scholars every year to attend top universities.  To date, over 300 GSK-EDB scholars have been sponsored and, in 2012, the trust was extended from universities in Europe and North America to include NUS (National University of Singapore) and INSEAD MBA students with GSK making its first hire of a Singapore-based GSK-EDB scholar in 2013.

Close

GSK-Singapore Academic Centre of Excellence (ACE)

ACE (Academic Centre of Excellence) is a virtual research network that encourages and facilitates multi-disciplinary innovation projects to be undertaken in partnership with researchers at A*Star (Agency for Science, Technology and Research), universities and hospital clinicians.

Established in 2010 in partnership with Singapore's EDB (Economic Development Board) and the academic community, ACE was the first of its kind in Asia.

Close

GSK-Singapore Partnership for Green and Sustainable Manufacturing

In 2010, GSK and Singapore's EDB (Economic Development Board) made a joint commitment to improve pharmaceutical and fine chemical manufacturing efficiency in Singapore. This commitment included a GSK and EDB-funded endowment of S$33 million to fund research that will:

  • build a strong capability in Singapore to meet the sustainable manufacturing challenges of the future for local industries
  • further enhance the working relationship between universities, institutes and local companies through interdisciplinary research in sustainability
  • enable Singapore to become a leader in sustainability research for pharmaceuticals and fine chemicals

As part of this partnership, GSK committed a further S$50 million into its Factory of the Future initiative in 2012 which seeks to reduce the company's carbon footprint through the use of a number of sustainable processes and green technologies. 

This initiative is part of a S$50 million endowment programme announced in 2009 to commemorate GSK's 50-years in Singapore and celebrate the opening of the Global Vaccines Manufacturing facility at Tuas.  GSK contributed S$30m to the endowment with the remaining S$20 million coming from the EDB.

Close

GSK-NIHA (NUS Initiative to Improve Health in Asia) Partnership

NIHA (NUS Initiative to Improve Health in Asia) is an integrative initiative to improve public health and healthcare delivery in Asia through improved research, governance and sustainable financing.

NIHA is made possible by a GSK and EDB (Economic Development Board)-funded endowment of S$17 million over 10-years (from 2010).   It is co-ordinated by NUS GAI (Global Asia Institute) in collaboration with the Lee Kuan Yew School of Public Policy, Yong Loo Lin School of Medicine and the NUS Business School.  NIHA also collaborates with other institutions with relevant experience in Singapore and internationally.

This initiative is part of a S$50 million endowment programme announced in 2009 to commemorate GSK's 50-years in Singapore and celebrate the opening of the Global Vaccines Manufacturing facility at Tuas.  GSK contributed S$30m to the endowment with the remaining S$20 million coming from the EDB.

Close

A*STAR R&D Consortium

In June 2013, GSK (along with Pfizer and Siemens) became a founding member of a new A*STAR (Agency for Science, Technology and Research) R&D Consortium Programme - Innovative Processing of Specialties and Pharmaceuticals (iPSP).

Launched by A*STAR’s ICES (Institute of Chemical and Engineering Sciences), the consortium offers a platform for pharmaceutical and specialty chemicals industry players to address various challenges such as costs, regulatory compliance and responsiveness in production and processes to bring drugs from trials to markets.

The consortium programme brings together industry leaders to address an increasingly urgent need to access emerging “next generation manufacturing” technologies that provide quantum change improvements in cost, quality, environmental impact and process robustness in pharmaceutical manufacturing processes. The advancement in technologies and adoption of best practices in processing technologies will help companies drive up productivity and maximise manpower development to maintain their competitive edge.

Close

Global Asia Management Programme

In 2014, GSK joined forces with Singapore's EDB (Economic Development Board) human capital division along with other partner companies (Rolls Royce and Applied Materials) to launch the Global Asia Management Programme.  The programme is designed to accelerate the career trajectories of participants through Global-Asia exposure opportunities, developing a global mindset and teaching selected individuals to work effectively across borders, in Asia and globally.  It is funded by the GSK-EDB Human Resource Development Fund.

Close